Q-omics provides the consensus-scored KRT35 profile across patient tissues and cancer cell-line models. KRT35 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in PCPG. Among the 18 cancer types available for tumor–normal comparison, KRT35 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, KRT35 RNA expression shows 6,495 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight PCPG, KICH, and STAD as cancer lineages where KRT35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT35 survival associations across molecular data types. KRT35 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT35 RNA expression–survival associations across cancer types. High KRT35 expression shows unfavorable associations in PCPG, BLCA, UCS, HNSC, MESO and READ. The PCPG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify PCPG as the clearest survival context for KRT35 RNA expression.
This table summarizes KRT35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRT35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT35 shows lower tumor expression in KIRC and higher tumor expression in KICH, BRCA, COAD, LUSC and KIRP. The KICH box plot shows higher KRT35 RNA expression in tumor versus normal tissue (log2 FC = +0.181, t-test p = .006).
This table shows molecular features associated with KRT35 in patient tissues and cancer cell lines. In patient samples, KRT35 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_NSCLC_LUAD.
